Fig. 2From: Radiotherapy in metastatic castration resistant prostate cancer patients with oligo-progression during abiraterone-enzalutamide treatment: a mono-institutional experienceProgression free survival for patients submitted to radiotherapy < 6 vs > 6 months after the start of androgen receptor targeted therapyBack to article page